Fisetin preserve lipid homeostasis in HFD-fed mice. Serum levels of lipid biochemical parameters in mice. (a) Triglyceride (TG), (b) Total cholesterol (TC), (c) LDL-C and (d) HDL-C... by Mahboobe Sattari (20622143)

Table_1_Cysteinyl Leukotriene Receptor Antagonists Associated With a Decreased Incidence of Cancer: A Retrospective Cohort Study.docx by Ha Young Jang (1522204)

“…The cancer risk showed a tendency to decrease rapidly when LTRAs were used in high dose (aHR = 0.56, 95% CI = 0.40–0.79) or for longer durations of more than 3 years (aHR = 0.68, 95% CI = 0.60–0.76) and 5 years (aHR = 0.33, 95% CI = 0.26–0.42). …”

Shiga toxin expression in O157 following treatment with hGRNL, bNK2A, and pNKL peptides. by Erika N. Biernbaum (12647386)

Subjects:

Multivariable logistic regression analysis of the relationship of the date of a PHC visit with new visits, types of health events, procedure, and outcome of visits. by Taizo Sakata (21567847)

Subjects:

PMC exhibits less sensitivity to decreasing signal-to-noise ratio (SNR) by Owen Puls (22340344)

Syndecan ectodomain fragments decrease endothelial resistance via rho kinase. by Melanie Jannaway (6703577)

“…(C) rhS4ED fragments significantly decreased TER (n = 8, p = 0.0002). (D) Fragments of non-glycosylated form of rhS4ED also generated significant decreases in TER (n = 5, p = 0.0011). …”

Schematic of training program during a 10-session heat acclimation intervention in national-level rowers. by Calvin P. Philp (12095878)

Subjects:

Decreased glycosylated α-DG and laminin levels distal to the glial dome in <i>Large</i>^{<i>myd/myd</i>} mice. by Shigefumi Morioka (8893511)

Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict... by Cecília Monteiro (13888010)

“…</p> <p>Native TTR levels increased by 56.8% while combined native + non-native TTR levels increased by 3.1% after 24 months of tafamidis treatment, implying that non-native TTR decreased. …”

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

K2 treatment increases access of a hydrophobic probe to the bacterial membrane of <i>K</i>. <i>pneumoniae</i>. by Estelle Ifrid (10076719)

Subjects:

Comparison in baseline variables between efficacy group and non-efficacy group. by Naruyoshi Gyoutoku (22537831)

Subjects:

Intracellular killing of <i>K</i>. <i>pneumoniae</i> mutants. by Estelle Ifrid (10076719)

Subjects:

K2 treatment renders <i>K</i>. <i>pneumoniae</i> more susceptible to intracellular killing. by Estelle Ifrid (10076719)

Subjects:

K2 is active at a concentration of 3 μM and above. by Estelle Ifrid (10076719)

Subjects:

Marker genes for the non-immune clusters. by Emilie Pollenus (10147748)

Comparison of physiological and perceptual measures of national-level rowing athletes taken during a 10-min submaximal rowing test performed at 95% of 30-min time-trial average pow... by Calvin P. Philp (12095878)

Subjects: